Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000153956 | SCV000203574 | pathogenic | not provided | 2013-12-11 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000153956 | SCV000490802 | pathogenic | not provided | 2019-08-07 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate a damaging effect in deficiency of lysosomal transport (Mancini et al., 1991); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; Not observed at a significant frequency in large population cohorts (Lek et al., 2016); This variant is associated with the following publications: (PMID: 2010546, 10947946, 12709150, 15805149, 10581036, 31589614) |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000588857 | SCV000699340 | pathogenic | Salla disease | 2017-07-17 | criteria provided, single submitter | clinical testing | Variant summary: The SLC17A5 c.533delC (p.Thr178Asnfs) variant results in a premature termination codon, predicted to cause a truncated or absent SLC17A5 protein due to nonsense mediated decay, which are commonly known mechanisms for disease. This variant was found in 8/118852 control chromosomes at a frequency of 0.0000673, which does not exceed the estimated maximal expected allele frequency of a pathogenic SLC17A5 variant (0.0023717). Multiple publications have cited the variant in compound heterozygote affected individuals. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as pathogenic. Taken together, this variant is classified as pathogenic. |
Baylor Genetics | RCV000588857 | SCV001163089 | pathogenic | Salla disease | 2024-03-12 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000588857 | SCV001232860 | pathogenic | Salla disease | 2024-01-28 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Thr178Asnfs*34) in the SLC17A5 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC17A5 are known to be pathogenic (PMID: 10581036, 10947946, 15172001). This variant is present in population databases (rs727504156, gnomAD 0.01%). This premature translational stop signal has been observed in individuals with sialic acid storage disorders (PMID: 10581036, 15805149). ClinVar contains an entry for this variant (Variation ID: 167693). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Institute of Medical Genetics and Applied Genomics, |
RCV000153956 | SCV001480119 | pathogenic | not provided | 2021-02-01 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Lab, |
RCV000588857 | SCV001572959 | pathogenic | Salla disease | 2020-06-04 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000153956 | SCV002022593 | likely pathogenic | not provided | 2021-06-24 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000588857 | SCV002027577 | pathogenic | Salla disease | 2021-09-05 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000005968 | SCV000026150 | pathogenic | Sialic acid storage disease, severe infantile type | 1999-12-01 | no assertion criteria provided | literature only | |
Counsyl | RCV000588857 | SCV001132286 | likely pathogenic | Salla disease | 2017-09-22 | no assertion criteria provided | clinical testing | |
Natera, |
RCV000588857 | SCV001453513 | pathogenic | Salla disease | 2020-09-16 | no assertion criteria provided | clinical testing | |
Undiagnosed Diseases Network, |
RCV000005968 | SCV004812052 | pathogenic | Sialic acid storage disease, severe infantile type | 2022-06-21 | no assertion criteria provided | clinical testing |